TALICIA
Peakomeprazole magnesium, amoxicillin and rifabutin
NDAORALCAPSULE, DELAYED RELEASEPriority Review
Approved
Nov 2019
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 4d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TALICIA is a fixed-dose oral combination of omeprazole magnesium, amoxicillin, and rifabutin in delayed-release capsule form, approved in 2019 for the eradication of Helicobacter pylori infection. The triple therapy works by combining a proton pump inhibitor with two antimicrobial agents to overcome resistance mechanisms. This formulation addresses treatment-resistant H. pylori infections where standard dual or triple therapies have failed.
$0.003BPart D
Peak16.1 years to LOETALICIA is in peak commercial lifecycle with modest Part D claims (~4,100 annually in 2023), suggesting a niche market with limited team expansion opportunities.
Mechanism of Action
Pharmacologic Class:
Rifamycin Antimycobacterial
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TALICIA has no reported linked job openings, indicating a small dedicated team or integration within a larger specialty infection franchise. Employment opportunities on this product are limited and likely concentrated in specialty sales and medical affairs rather than brand management.
External Resources
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.